Both the tricyclic and specific serotonin reuptake inhibitor classes of antidepressants act primarily by inhibiting the reuptake of released serotonin by the human serotonin reuptake transporter (hSERT). In this article, the authors describe the use of a fluorescent substrate of the transporter (4-(4-(dimethylamino)-styrl)-N-methylpyridinium, ASP) to develop a microplate-based highthroughput screen for hSERT function. The assay is sensitive to known inhibitors of serotonin uptake, including fluoxetine (Prozac), with the correct rank order of potency and IC 50 values close to those reported in the literature for tritiated serotonin uptake. The authors also describe the validation of the assay for natural product screening using a test set of 2400 pure phytochemicals and 80 plant extracts. The mean Z´ of the screened plates was 0.53. Hit rates, confirmation rates, and validation of the hits in a "classical" assay for serotonin uptake are all reported. The assay can also be read in "high-content" mode using a subcellular imaging device, which allows direct detection of possible assay interference by acutely cytotoxic compounds. Among the compounds identified were several previously reported inhibitors of the hSERT, as well as compounds having structural similarity to the tricyclic antidepressant drugs. (Journal of Biomolecular
INTRODUCTION
T HE MONOAMINE THEORY OF DEPRESSION was proposed more than 40 years ago, 1 yet a deficiency of serotonin signaling remains central to our understanding of depressive illness today. The 3 classes of antidepressive drug available all act by enhancing brain levels of serotonin. The monoamine oxidase inhibitors (MOAs) prevent the breakdown of serotonin, thus increasing the concentrations in the presynaptic nerve termini, whereas the tricyclic antidepressants (TCAs) and the specific serotonin reuptake inhibitors (SSRIs, including Prozac) both inhibit the reuptake of released serotonin by the serotonin reuptake transporter (hSERT), thus enhancing and prolonging serotonin signaling events. Recently, the specific serotonin reuptake inhibitors have also been found to be effective in treating other disorders, including posttraumatic stress disorder, social anxiety disorder, panic disorder, obsessive compulsive disorder, seasonal affective disorder, and premenstrual dysphoric disorder. 2, 3 There is therefore renewed interest in developing inhibitors of hSERT and of related monoamine reuptake transporters. Our interest is in identifying naturally occurring inhibitors of serotonin uptake from fractionated plant extracts for development as nutritional supplements.
The currently available serotonin reuptake inhibitors were discovered serendipitously (in the case of the TCAs 4 ) or by design (in the case of the SSRIs). 5 Since the cloning of hSERT in 1993, 6,7 a molecular-based screening approach has become possible. Two types of assay are currently available: various known inhibitors of hSERT including fluoxetine, paroxetine, imipramine, and citalopram can be bought in tritiated form, and, together with membranes from mammalian cells which overexpress hSERT, used to construct a ligand displacement assay using SPA technology. However, we preferred a functional assay for screening as it is known that some compounds (e.g., hyperforin, the putative active principle of St. John's wort) affect serotonin uptake without inhibiting paroxetine binding. 8 The existing functional assay for hSERT function is uptake of tritiated serotonin into hSERT-expressing Screening and Early Efficacy Group, Human Nutrition Research and Development, DSM Nutritional Products, Kaiseraugst, Switzerland. cells followed by removal of unincorporated label and quantification by liquid scintillation counting. Unfortunately, this assay is heterogeneous, involving either a plate wash or a filtration step, resulting in the production of radioactive liquid waste, and is therefore not attractive as a high-throughput screen.
The fluorescent molecule 4-(4-(dimethylamino)-styrl)-N-methylpyridinium (ASP, Fig. 1 ) has been used to stain nerve termini 9 and is a known substrate for the organic cation transporter (OCT). 10 Schwartz et al. 11 recently reported that ASP may be used to measure the biophysical properties of monoamine transporters as its accumulation in norepinephrine reuptake transporter (hNET)−expressing cells (measured by fluorescence microscopy) was Na + , Cl − , and temperature dependent. In this article, we describe the use of ASP to develop a microplate-based high-throughput screen for hSERT function, using a microplate fluorimeter. Alternatively, the assay may be measured using a subcellular imaging plate reader (e.g., the Cellomics Array-Scan Vti). The results of a pilot screen of more than 2000 pure natural phytochemicals, from which all known classes of hSERT inhibitors contained therein were reidentified, and the validation of the novel hits in a well-established secondary (tritiated serotonin uptake) assay are also reported.
MATERIALS AND METHODS
Compounds for screening were obtained from Sigma Aldrich (Steinheim, Germany), Apin Chemicals Ltd. (Abingdon, UK), Indofine Chemical Company (Hillsborough, NJ), and Microsource Discovery Systems (Gaylordsville, CT) and were usually of 95% purity. The 80 samples from plants were extracted with different solvents (50 via solid-phase extraction using carbon dioxide, 30 via alcoholic extraction) and dissolved in DMSO at 1 mg/mL and 10 mg/mL. All other reagents were obtained from Sigma Aldrich unless otherwise stated.
Cell culture
HEK-293 cells stably expressing hSERT were obtained from R. Blakely (Vanderbilt University, TN 12 ). The cells were routinely grown on flasks precoated with poly-L-lysine (Sigma), in Dulbeco's Modified Eagles Medium (Bioconcept, Allschwil, Switzerland) containing 10% dialysed fetal calf serum, penicillin, streptomycin, L-glutamine, and the antibiotic G418 (all from Invitrogen, Paisley, UK), and passaged by trypsinization.
ASP assay
Forty-eight hours prior to assay, cells from 80% confluent flasks were harvested by trypsinization and seeded (75,000 per well) into poly-D-lysine-coated 96-well plates (Becton Dickinson, Bedford, MA). Immediately prior to assay, the medium was exchanged for Krebs Ringers HEPES (KRH) buffer (130 mM NaCl, 1.3 mM KCl, 2.2 mM CaCl 2 , 1.2 mM MgSO 4 , 1.2 mM KH 2 PO 4 , 10 mM HEPES, pH 7.3) supplemented with glucose (1.8 g/L), ascorbic acid (100 µM), and pargyline (100 µM). ASP (Sigma Aldrich) was added (final concentration 1 µM) and incubated at 37 °C, 5% CO 2 , 95% humidity for 60 min. Unincorporated ASP was removed by washing (3 times with 300 µl KRH containing 1 mM imipramine) and the cells lysed by addition of sodium dodecyl sulfate (SDS) to 1% final concentration. The incorporated ASP was quantified by fluorescence intensity (λex = 485 nm, λem = 620 nm) using the Analyst (Molecular Devices Corporation, Sunnyvale, CA). The assay was automated using the Cy-Bio Cy-Bi Well for compound addition, the Labsystems multidrop for ASP addition, and the Titertek MAP-C system for plate washing.
High-content assay
The assay was performed as described above with the following exceptions: the cells were seeded at a concentration of 30,000 cells per well to allow resolution of individual nuclei in the images, Hoechst 33342 (Molecular Probes, Eugene, OR) was added at a final concentration of 1 µg/mL for the final 30 min of the incubation with ASP to stain the nuclei, and the postwash KRH buffer was supplemented with 1.8 g/L glucose to maintain the viability of the cells during measurement. The cells were imaged using the Cellomics ArrayScan Vti (Pittsburgh, PA) highcontent reader using the cell health profiling bioapplication with the 20 × objective. A minimum of 250 cells per well were imaged (λex = 475 nm, λem = 600 nm), or a maximum of 10 fields.
Tritiated serotonin uptake assay
On the day of assay, cells from 80% confluent flasks were harvested by gentle washing with warm phosphate-buffered saline (PBS). Cells were then washed once by centrifugation and resuspended in Krebs Ringers bicarbonate buffer (Sigma Aldrich) supplemented with 100 µM pargyline, 2.2 mM CaCl 2 , 100 µM ascorbic acid, and 10 mM HEPES (pH 7.3), and aliquoted into round-bottomed polypropylene 96-well microplates (Nunc, Roskilde, Denmark) at 10,000 cells per well. Serotonin uptake into the cells was determined by addition of radiolabeled (3H) serotonin (Amersham, Buckinghamshire, UK) to a concentration of 20 nM and incubation for 40 min at 37 °C with gentle shaking. At the end of this time, unincorporated label was removed by filtration through Unifilter 96 GF/B plates (PerkinElmer, Wellesley, MA) using a Tomtec Mach III M cell harvester. The incorporated serotonin retained on the plates was quantified by liquid scintillation counting using Microscint-40 and measured using a Topcount (PerkinElmer) with quench correction.
All percentage inhibition values quoted were calculated relative to the controls (wells containing 0.25% DMSO or 0.25% DMSO + 200 µM imipramine) from the same plate. Curve fitting was performed using Origin 7.0, and screening data analysis was performed using MDL Assay Explorer 2.2.
RESULTS
In the first round of experiments, hSERT-expressing HEK 293 cells were incubated with ASP at a range of concentrations from 0.1 to 10 µM over a time course of 10 to 60 min in the presence and absence of 200 µM imipramine, followed by removal of unincorporated ASP by washing. At each time point, the specific ASP uptake rate tends toward saturation as the ASP concentration increases, as expected for an enzyme reaction ( Fig. 2a) . The K m for ASP at the hSERT transporter was estimated from these titrations to be between 9.9 and 20.0 µM. The highest signal to background ratios and Z´factors (2.5 and 0.73, respectively) were obtained with 1 µM ASP, incubated with the cells for 60 min. Although 1 µM is below the estimated K m for ASP at the hSERT transporter, this concentration was chosen for all further experiments to maximize the assay robustness. The time course was subsequently repeated to confirm reaction linearity under the chosen assay conditions, as shown in Figure 2b . Untransfected HEK cells were also included in this experiment for comparison. The rate of ASP uptake by the untransfected HEK cells was similar to that seen with hSERT transfected cells in the presence of an excessive concentration of imipramine (200 µM). In this experiment, the signal-to-background ratio and Z´factor for the hSERT transfected cells after 60 min of incubation with ASP alone compared to ASP + 200 µM imipramine were 2.1 and 0.80, respectively.
On the basis of these results, we decided to proceed with a high-throughput screening (HTS) assay development. Titration of DMSO into the assay showed that, typically for this class of transporters, hSERT function was compromised by concentrations of DMSO in the assay > 0.1%, and at > 0.3%, the Z´ dropped to less than 0.5 (data not shown). A final DMSO concentration of 0.25%, which gave acceptable assay performance while allowing the highest possible screening concentration of test compounds, was therefore chosen for all further experiments.
Prior to screening, the assay was validated using a panel of known serotonin reuptake inhibitors, representing both the specific serotonin reuptake inhibitors and the tricyclic antidepressants. Typical dose-response curves from 1 experiment are shown in saturation at 100% inhibition. The results of 3 independent IC 50 determinations are shown in Table 1 .
The automated assay was tested by screening a set of 2400 pure natural products plus 80 plant extracts, first in singlicate, followed by triplicate reconfirmation of the primary hits. The pure compounds were screened at a concentration of 12.5 µM and the plant extracts at 0.0025 and 0.025 mg/mL final concentrations in the assay, with a resultant DMSO concentration of 0.25%. Of the plates screened, 30 of 32 passed plate quality control (QC; Zǵ reater than 0.4 for the on-plate controls), with Z´ values for the passed plates falling between 0.41 and 0.77. The mean Z´ for the 32 plates screened was 0.53 ± 0.12. The mean Z´ for the 30 passed plates was 0.55 ± 0.1. The strongest determinant of Z´ among this set of plates appears to be the degrees of variation (scatter) among the uninhibited controls (R 2 = 0.28), followed by the signal-to-background ratio (R 2 = 0.17). A scattergram showing the percentage inhibitions for all the control and test wells in the screen is shown in Figure 4a . The standard deviation in the uninhibited controls across all 32 plates was determined to be 9.1%. A histogram showing the distribution of percentage inhibitions for all the test wells is shown in Figure 4b . The distribution of activities is approximately normal, with a modal class of -10.0% to 0.0% inhibition, a mean of -6.9%, and a standard deviation of 63.6%. Because the mean and standard deviation may be strongly influenced by a skewed distribution and by extreme outliers, it may be preferable to consider the median value instead, which, for the ASP pilot screen, is -3.8% inhibition. The corresponding interquartile range is 36.3% (13.8% minus -22.5%). All the wells that gave greater than 25% inhibition (approximately 3 standard deviations or more from the mean of the uninhibited controls) in the primary screen were cherry-picked and retested in triplicate under the same conditions. The Z´ factors for all 32 primary screening plates and the subsequent confirmation rate (the percentage of compounds showing a mean percentage inhibition of 25% or greater in triplicate reconfirmation) for the hits derived from each plate are shown in Figure 5 .
All the confirmed pure compound hits from the ASP screen were subsequently tested again in triplicate in the ASP assay but this time with coaddition of imipramine (final concentration 200 µM) to dissect whether their activity was due to inhibition of hERT-dependent or hERT-independent ASP uptake. Actives in this so-called control assay were defined as those wells that showed fluorescence intensity more than 3 standard deviations lower than that of the control wells-that is, less than (mean fluorescence intensity control wells) -(3 × standard deviation fluorescence intensity of the controls wells). Of the 101 substances tested, 23 met the above criteria and were excluded from further follow-up.
The ASP uptake assay was also converted to a high-content assay, measured using the Cellomics ArrayScan Vti imaging platform, simply by omitting the lysis step and reading the plates immediately following the last wash step. The signal-tobackground ratio and Z´ parameters for the assay measured on the ArrayScan were very similar to those previously found for the high-throughput assay (data not shown). The IC 50 for fluoxetine was also similar (5.3 µM). Figure 6 shows images of The potential advantages of the high-content reading mode were tested using one false positive, alpha-hederin, which was identified as described above. The results are shown in Figure 7 .
hSERT function, as measured by either total well ASP fluorescence (Analyst) or the mean ASP intensity per cell (ArrayScan), is approximately constant up to 0.3 µM alpha-hederin, above which point the measured ASP uptake appears to decrease sharply. The explanation for this is readily apparent from the plot of cell count per field, measured in parallel on the ArrayScan, which also shows a sharp decrease between 0.3 and 1.0 µM alpha-hederin. To further validate the ASP uptake assay as a functional assay for the hSERT, all the confirmed active pure compounds that were not active in the control assay were tested, at the same concentration as used above, for their ability to inhibit the uptake of tritiated serotonin into the same hSERT-expressing HEK cell line as used above under similar conditions. Of the 78 compounds tested, 63 caused greater than 25% inhibition of tritiated serotonin uptake, a validation rate of 80.1%.
DISCUSSION
The fluorescent molecule ASP was successfully used as a substrate for hSERT to set up a high-throughput screen to measure transporter function in stably transfected HEK cells.
Experiments to probe the hSERT dependence of the ASP uptake confirmed that untransfected HEK cells do display some time-dependent increase in ASP fluorescence, although substantially lower than for the cells expressing hSERT, and very similar to the uptake measured for hSERT expressing cells in the presence of a saturating concentration of imipramine. We have shown that this "background" or nonspecific uptake is also a cell-dependent process by measuring the fluorescence intensity following incubation of plates in the presence and absence of cells, ASP, and imipramine (all combinations). In the absence of cells (with or without imipramine), the fluorescence measured was approximately 3-fold less than in the presence of cells + 200 µM imipramine and indistinguishable from the fluorescence measured from plates to which ASP had not been added (data not shown). This cell-dependent but hSERTindependent ASP uptake could be due to passive diffusion of ASP through the cell membrane or transport by other transports. Inhibitors of the human norepinephrine reuptake transporter (nisoxetine), the human dopamine reuptake transporter (GBR12935), or the organic cation transporter (famotidine and ranitidine) did not affect the non-hSERT-dependent uptake of ASP at concentrations up to 100 µM (data not shown).
Validation of the assay with a panel of known serotonin reuptake inhibitors of different structural classes showed that the potency of the 3 drugs-fluoxetine (an SSRI), imipramine, and desimipramine (both TCAs)-in the ASP assay are in the same rank order as their published binding constants. 13 Comparison of the ASP data with literature IC 50 values suggests that the ASP assay may be approximately 3-fold less sensitive to these inhibitors than the tritiated serotonin uptake assay. 14 This may be due to the fact that tritiated neurotransmitter uptake assays are usually performed using concentrations of labeled substrate several orders of magnitude below their K m . A pilot library of 2400 pure phytochemicals and 80 plant extracts, selected to contain several known classes of compounds/ extracts expected to show activity in the assay, was screened to assess the hit rates and confirmation rates obtained using the new assay. The hit rates in the primary screen, using various percentage inhibition cut-offs, are given in Table 2 , together with the corresponding confirmation rates in triplicate retest. It is possible that a number of the confirmed hits may be "false positives," whose activity is due to inhibition of non-hSERT-dependent ASP uptake processes, as discussed above. This risk was mitigated in part by testing the effect of the triplicate confirmed hits on the "background" or nonspecific uptake of ASP-that is, in the absence of functional hSERT (achieved by coaddition of 200 µM imipramine). Furthermore, because the background ASP uptake is also a cell-dependent process, the control assay should also be sensitive to any compounds whose apparent activity is due to acute cytotoxicity. Of all the confirmed active pure compounds identified in the ASP assay, 22.7% did show activity in this socalled control assay and could be immediately excluded from further investigation. Many of these compounds were found to be triterpene saponins of the oleanane type (e.g., alpha-hederin, compounds that are known to be haemolytic). 15 Importantly, the control assay did not exclude any of the known active compounds (see below) contained in the library.
An alternative approach to excluding compounds that interfere in the assay due to acute cytotoxicity is to measure the ASP uptake using a high-content subcellular imaging platform. In this mode, it is possible to directly compare the ASP uptake with the cell count per field, with the added advantage that the uptake is normalized for cell number, because the ASP intensity within the cytoplasm of each individual cell is measured, thus compensating for any variation in cell growth across plates. The advantage of the high-content measurement mode was illustrated by experiments using 1 compound, alpha-hederin, identified as a false positive in the ASP control assay described above. Using the high-content imaging approach, the cell count per field could be monitored in parallel with the ASP uptake per cell to detect gross changes in cell viability. The sensitivity of the assay to acute cytotoxicity could be further increased by the simultaneous inclusion of a membrane permeability dye or mitochondrial mass/potential sensor. The disadvantage of the high-content format in the case of the ASP assay is that the fluorescence measurement was not stable following the last washing step, presumably due to ASP leakage or active transport out of the cell, thereby limiting the assay to very small numbers of plates.
It is also possible that the hits from the ASP assay could represent artifacts of using a nonphysiological substrate. To address this question, the confirmed active pure compounds from the pilot screen that were not active in the control assay were further tested in the "classical" assay for measurement of hSERT activity (i.e., uptake of tritiated serotonin into the hSERT-expressing cells). Encouragingly, 80.1% of all the confirmed hSERT-specific compounds from the ASP screen also showed inhibition of uptake of tritiated serotonin into the same cells under similar assay conditions. Among the compounds identified from a pilot screen using the ASP assay, we found several structural classes of compounds previously reported to inhibit serotonin uptake via the hSERT, including hyperforin 16 (the putative active principle contained in St. John's wort) and the quinidines 17 (quinine, quinidine, cinchonine, and cinchonidine). It was also notable that a number of the active natural products identified in the screen (e.g., harmine, eleagin, tryptoline) contained a tricyclic ring structure similar to the structure of the tricyclic antidepressants (e.g., imipramine; Fig. 8 ). Furthermore, 1 newly identified serotonin uptake inhibitor from the ASP screen, apigenin, has recently been reported to show antidepressant activity in the Porsolt forcedswim test, 18 further validating the ASP assay as a functional assay for natural product screening.
In addition to the pure compound set, 80 unfractionated plant extracts were also screened using the ASP assay at 2 concentrations, of which 3 were determined to be active at 1 or both concentrations. One of the active extracts was later revealed to be Hypericum perforatum (St. John's wort), the well-known herbal antidepressive remedy. At a concentration of 25 µg/mL in the assay, the extract gave 86.0% inhibition of ASP. This is consistent with that expected from the content of hyperforin in the extract (independently determined to be 38.2%), given that hyperforin at 12.5 µM (equivalent to 6.7 µg/mL) gave 35.6% inhibition in the same assay. The ASP uptake assay for hSERT function has subsequently been used to test more than 600 fractionated extracts of plant material, totaling more than 38,000 individual fractions, which, after bioactivity-guided de-replication, have yielded a number of compounds with previously unreported serotonin reuptake inhibition properties.
